Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized Controlled Trial to Decrease Suicidal Thinking Using Ketamine

To see complete record on, please visit this link

Id: NCT02418702

Organisation Name: United States Naval Medical Center, San Diego

Overal Status: Withdrawn

Start Date: August 2016

Last Update: September 3, 2019

Lead Sponsor: United States Naval Medical Center, San Diego

Brief Summary: Depression treatment typically is slow acting. Patients presenting with acute suicidality have few immediate treatment options. However, sub-anesthetic doses of ketamine have been now widely tested as a rapid-acting treatment for depression. Gregory Larkin et al at Yale showed this could be applied to suicidal patients, with 14 of 15 participants showing remission of suicidal thinking within 40 min of the administration of ketamine, with 13 showing lasting remission out to 10 days. No serious side effects were reported. This project proposes to conduct a randomized, placebo-controlled trial of this, same intervention in military patients recently hospitalized for suicidal thinking. After being assessed, and giving informed consent, participants would receive 0.2mg/kg ketamine or placebo. Their suicidal thinking, depression, and other symptoms would be monitored acutely for 240 min after drug infusion, and the for lasting changes the next day, at hospital discharge, 2 weeks, and 10 weeks. Potential adverse events will be monitored via the electronic medical record for up to a year.

  • Depression
  • Suicide

Total execution time in seconds: 0.21742296218872